Immunovant Statistics
Share Statistics
Immunovant has 146.78M shares outstanding. The number of shares has increased by 12.01% in one year.
| Shares Outstanding | 146.78M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.13% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 62.37M |
| Failed to Deliver (FTD) Shares | 103.68K |
| FTD / Avg. Volume | 12.7% |
Short Selling Information
The latest short interest is 13.10M, so 8.93% of the outstanding shares have been sold short.
| Short Interest | 13.10M |
| Short % of Shares Out | 8.93% |
| Short % of Float | 21.05% |
| Short Ratio (days to cover) | 19.69 |
Valuation Ratios
The PE ratio is -16.83 and the forward PE ratio is -9.66.
| PE Ratio | -16.83 |
| Forward PE | -9.66 |
| PS Ratio | 0 |
| Forward PS | 128.4 |
| PB Ratio | 7.07 |
| P/FCF Ratio | -20.34 |
| PEG Ratio | n/a |
Enterprise Valuation
Immunovant Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 13.7, with a Debt / Equity ratio of 0.
| Current Ratio | 13.7 |
| Quick Ratio | 13.7 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.02 |
| Cash Flow / Debt | -1552.37 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.42% and return on capital (ROIC) is -45.85%.
| Return on Equity (ROE) | -0.42% |
| Return on Assets (ROA) | -0.39% |
| Return on Capital (ROIC) | -45.85% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.25M |
| Employee Count | 207 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 567.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -38.42% in the last 52 weeks. The beta is 0.71, so Immunovant 's price volatility has been higher than the market average.
| Beta | 0.71 |
| 52-Week Price Change | -38.42% |
| 50-Day Moving Average | 28.94 |
| 200-Day Moving Average | 29.32 |
| Relative Strength Index (RSI) | 44.22 |
| Average Volume (20 Days) | 816.28K |
Income Statement
In the last 12 months, Immunovant had revenue of $0 and earned -$259.34M in profits. Earnings per share was $-1.88.
| Revenue | 0 |
| Gross Profit | -231.00K |
| Operating Income | -282.71M |
| Net Income | -259.34M |
| EBITDA | -269.98M |
| EBIT | - |
| Earnings Per Share (EPS) | -1.88 |
Balance Sheet
The company has $635.37M in cash and $138.00K in debt, giving a net cash position of $635.23M.
| Cash & Cash Equivalents | 635.37M |
| Total Debt | 138.00K |
| Net Cash | 635.23M |
| Retained Earnings | -825.68M |
| Total Assets | 515.71M |
| Working Capital | 440.72M |
Cash Flow
In the last 12 months, operating cash flow was -$214.23M and capital expenditures -$360.00K, giving a free cash flow of -$214.59M.
| Operating Cash Flow | -214.23M |
| Capital Expenditures | -360.00K |
| Free Cash Flow | -214.59M |
| FCF Per Share | -1.55 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
IMVT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -7.14% |
| FCF Yield | -5.55% |
Analyst Forecast
The average price target for IMVT is $50.5, which is 91.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $50.5 |
| Price Target Difference | 91.9% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
Scores
| Altman Z-Score | 32.45 |
| Piotroski F-Score | 3 |